Rezultati - Purnima Pathak

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil

    PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with... od Tristan Curteis, David Chandiwana, Purnima Pathak, Brad Lanoue, Anna Maria Buehler, Radost Pencheva, J. Smith-Tilley

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Patient Preferences for HR+/HER2‒ Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment

    Patient Preferences for HR+/HER2‒ Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment od Victoria Harmer, Cathy Ammendolea, Mandy Ryan, Frances Boyle, Gustavo Werutsky, D. El Mouzain, Deborah A. Marshall, Caitlin Thomas, Sebastian Heidenreich, Hui Lü, Nicolas Krucien, J Payan, Dawn Aubel, Andriy Danyliv, Purnima Pathak, Nadia Harbeck

    Izdano 2025
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer

    Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer od Debu Tripathy, Tristan Curteis, Sara A. Hurvitz, Denise A. Yardley, Fábio Franke, K. Govind Babu, Paul Wheatley‐Price, Young‐Hyuck Im, Radost Pencheva, Lucy A. Eddowes, Pierre-Alexandre Dionne, David Chandiwana, Purnima Pathak, Brad Lanoue, Nadia Harbeck

    Izdano 2022
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

    233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy... od Peter A. Fasching, Nadia Harbeck, Guy Jérusalem, Marco Colleoni, Patrick Neven, F. Franke, Michelino De Laurentiis, Debu Tripathy, Miguel Martín, G Babu, Denise A. Yardley, Paul Wheatley‐Price, Arlene Chan, Rafael Villanueva-Vázquez, Arndt Nusch, Ennan Gu, Hao Hu, Purnima Pathak, Astrid Thuerigen, Aditya Bardia

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: